APLS241115C43000
- 0.00
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Apellis Pharmaceuticals Analyst Ratings
UBS Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $55
Apellis Pharmaceuticals Price Target Cut to $30.00/Share From $43.00 by Wells Fargo
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $40 From $65, Maintains Outperform Rating
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $75
Apellis Pharmaceuticals (APLS) Receives a Hold From Piper Sandler
Apellis Pharmaceuticals Is Maintained at Buy by B of A Securities
Strategic Positioning and Strong Efficacy Drive 'Buy' Rating for Apellis Pharmaceuticals
Apellis Pharmaceuticals: Hold Rating Amid Revenue Miss and Financial Challenges
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $25 From $27, Maintains Neutral Rating
Apellis Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $25 Price Target
Evercore Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating
Citi Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $63
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $35 to $95
Apellis Pharmaceuticals (APLS) Gets a Buy From TD Cowen
Analysts' Opinions Are Mixed on These Healthcare Stocks: Universal Health (UHS), Apellis Pharmaceuticals (APLS) and Zura Bio (ZURA)